Global Headache Disorders Market, By Type (Migraine, Tension-type Headache, Cluster Headache, Medication-overuse Headache, Others), Diagnosis (Complete Blood Count, Skull X-rays, Sinus X-rays, CT Scan, Magnetic Resonance Imaging (MRI), Others), Treatment (Medication, Heat Therapy, Diet Changes, Acupuncture, Oxygen Therapy), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Headache Disorders Market Analysis and Size
It is projected that over half of the adult population has witnessed a headache at least once in the previous year. Recurring headache disorders are associated with personal and societal costs of pain, disability, reduced quality of life, and financial cost. Only a small proportion of people having headache issues are diagnosed appropriately by physicians. Headache is underappreciated, under-diagnosed, and under-treated worldwide. Most of the currently approved drugs assign for the acute form of the condition, which is further led by generic triptans as the first-line treatment.
Data Bridge Market Research analyses a growth rate in the headache disorders market in the forecast period 2023-2030. The expected CAGR of headache disorders market is tend to be around 6.4% in the mentioned forecast period. The market was valued at USD 3.99 billion in 2022, and it would grow up to USD 6.55 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Headache Disorders Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015 - 2020)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Type (Migraine, Tension-type Headache, Cluster Headache, Medication-overuse Headache, Others), Diagnosis (Complete Blood Count, Skull X-rays, Sinus X-rays, CT Scan, Magnetic Resonance Imaging (MRI), Others), Treatment (Medication, Heat Therapy, Diet Changes, Acupuncture, Oxygen Therapy), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Hikma Pharmaceuticals PLC (U.K.), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), Boehringer Ingelheim International GmbH. (Germany), Dr. Reddy’s Laboratories Ltd. (India), Gilead Sciences, Inc. (U.S.), Amgen Inc. (U.S.), AbbVie Inc. (U.S.), Lilly (U.S.)
Headache disorders is the most widespread nervous system disorders which are typically characterized by consistent headaches. Headache is an extreme and disabling symptom of a few major headache disorders, which includes migraine, cluster headache, tension-type headache and others. Another incident cause of headache is overuse of medication. Antipsychotic medications, antiseizure medications, calcium channel blockers, antidepressants, and nonsteroidal anti-inflammatory drugs (NSAIDs) are the numerous drugs used in the treatment of headache disorders.
Global Headache Disorders Market Dynamics
- Rising Cases of Depression
The increasing number of cases of depression is a primary factor boosting the headache disorders market's growth rate during the forecast period of 2023-2030. Unhealthy lifestyle of people such as high alcohol consumption, severe changes in eating or sleeping pattern are the major risk factors which is expanding the frequency of depression and further causing headache. Additionally, emotional stress associated with family and friends, school or work is anticipated to boost the market’s growth rate during the forecast period.
- Increased Healthcare Expenditure
A major factor prompting the growth rate of headache disorders market is the increasing healthcare expenditure that helps in improving its improved infrastructure. Moreover, numerous government organizations aims to improve the healthcare infrastructure by growing funding and this will in turn influence the market dynamics. Thus, it boost the market growth.
- Increasing Demand of Preventive Treatment
Preventive or prophylactic treatment which includes prescription of off-label and generic medications named beta-blockers such as atenolol and propranolol, anti-epileptics such as topiramate, and divalproex sodium. Presently, Allergan’s Botox, Amgen/ Novartis’s Aimovig, and Teva’s Ajovy (CGRP mAb) are the only drugs that are approved for migraine prevention. Though, Botox requires more than 30 injections across the forehead, shoulders, and neck and does not provide relief from episodic migraine.
- Increased R&D Activities
Ongoing research focuses on using novel mechanisms of action such as corticotrophin receptor antagonism, CGRP-based receptor and ligand inhibition, and nitrous oxide inhibition. Wide approval of CGRP monoclonal antibodies is one of the major developments in the preventive market. Though numerous companies are anticipated to grow in the next two years, Amgen and Novartis are poised to benefit from Aimovig’s first-mover status, favourable reimbursement scenario, and easy to use the pen-device mode of administration. In May 2018, the drug was launched in North America and in Europe in July 2018 and has observed a positive response from patients and healthcare providers alike.
- Lack of Skilled Professionals
Absence of knowledge among healthcare professionals, poor awareness among the public, and the measures undertaken by the government to decrease the healthcare expenditure are the major barriers of the market.
This headache disorders market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the headache disorders market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Headache Disorders Market
During the COVID-19 pandemic, the pharmaceutical and drug research industries were witnessing a surge in demand. The headache disorders market is being impacted by the virus. Several treatments for COVID-19 were being tested by the pharmaceutical industry. In addition to this, migraine drug testing for COVID-19 were having a major impact on the market.
The headache disorders market is keeping a tab of drug compositions and effects. Demand will increase due to the considerable research into the headache disorders sector. In addition to this, in the upcoming years, a greater choice of medications will be available. All of these will assist the headache disorders market
- In 2021, FDA had approved the first and only oral CGRP receptor antagonist called QULIPTA™, which is particularly developed for the preventive treatment of migraine. CGRP and its receptors are used for nervous system that is related with migraine pathogenesis, and CGRP levels have been found to be more during migraine attacks in studies. QULIPTA is a once-daily medication that blocks CGRP. It comes in three different dosage forms including 10 mg, 30 mg, and 60 mg.
Global Headache Disorders Market Scope
The headache disorders market is segmented on the basis of type, diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Tension-type headache
- Cluster Headache
- Medication-overuse Headache
- Complete Blood Count
- Skull X-rays
- Sinus X-rays
- CT Scan
- Magnetic resonance imaging (MRI)
- Heat Therapy
- Diet Changes
- Oxygen Therapy
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Headache Disorders Regional Analysis/Insights
The headache disorders market is analyzed and market size insights and trends are provided by type, diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.
The major countries covered in the headache disorders market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market due to the increasing incidence of headache disorders and growing healthcare expenditure. Moreover, increasing focus of major market players on novel technology will enhance the market’s growth rate in this region.
Asia-Pacific is considered to grow in the forecast period because of the increasing number of elderly population in this region. Furthermore, development of healthcare infrastructure and increasing government initiatives will boost the market’s growth rate in this region
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Headache Disorders Share Analysis
The headache disorders market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to headache disorders market
Key players operating in the headache disorders market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (U.S.)
- Abbvie, Inc (Ireland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Bayer AG (Germany)
- Boehringer Ingelheim International GmbH. (Germany)
- Dr. Reddy’s Laboratories Ltd. (India)
- Gilead Sciences, Inc. (U.S.)
- Amgen Inc. (U.S.)
- Lilly (U.S.)